Abstracts tagged "Animal Model"

Abstract Number: 0031 • ACR Convergence 2024
Beyond Pain and Inflammation: Intra-articular Liraglutide’s Comprehensive Benefits on Synovial Health and Cartilage in Osteoarthritis Compared to Dexamethasone
Coralie Meurot¹, Celine Martin¹, Margot Vieubled¹, Jerome Breton¹, Indira Toillon², Revital Rattenbach³ and Francis Berenbaum², ¹4Moving Biotech, lille, France, ²Sorbonne University, Paris, France, ³4Moving Biotech, Paris, France
Background/Purpose: Osteoarthritis (OA) is an age-related joint disease that causes chronic pain and limited mobility. Patients mainly have access to therapies aimed at reducing inflammation…
Abstract Number: 0923 • ACR Convergence 2024
Immunization of Arthritis Prone Mice with Malondialdehyde-Acetaldehyde Modified Vimentin Induces Post-Translational Protein Modifications and Extracellular Matrix Deposition in Heart Tissues
Kimberley Sinanan¹, Wenxian Zhou², Michael Duryee¹, Nozima Aripova¹, Jill Poole¹, Carlos Hunter¹, Amy Nelson¹, Tate Johnson¹, Daniel Anderson³, Ted Mikuls¹ and Geoffrey Thiele¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Bellevue, NE, ³University of Nebraska Medical Center, Durham, NC
Background/Purpose: Recent studies have highlighted the importance of malondialdehyde-acetaldehyde (MAA)-modified proteins and resulting immune responses in the pathogenesis of rheumatoid arthritis (RA). MAA adducts have…
Abstract Number: 2078 • ACR Convergence 2024
Increased RAGE Expression in Myositis
Madison King¹, Rita Spathis², Elizabeth Bagley¹ and Melissa Morales³, ¹Binghamton University, Johnson City, NY, ²Binghamton University School of Pharmacy and Pharmaceutical Sciences, Johnson City, NY, ³SUNY Binghamton, Johnson City, NY
Background/Purpose: Myositis is a broad term for a group of rare autoimmune diseases that cause persistent muscle inflammation, weakness, and fatigue. Currently, first-line treatment for…
Abstract Number: 0032 • ACR Convergence 2024
Increased Expression of Malondialdehyde-Acetaldehyde and Citrullinated Proteins in Myocardial Tissues During the Early Evolution of Collagen-Induced Arthritis
Wenxian Zhou¹, Michael Duryee², Nozima Aripova², Jill Poole², Carlos Hunter², Amy Nelson², Tate Johnson², Daniel Anderson³, Geoffrey Thiele² and Ted Mikuls², ¹University of Nebraska Medical Center, Bellevue, NE, ²University of Nebraska Medical Center, Omaha, NE, ³University of Nebraska Medical Center, Durham, NC
Background/Purpose: The risk of heart failure (HF) is increased in patients with rheumatoid arthritis (RA), although mechanisms of myocardial dysfunction underlying HF development in RA…
Abstract Number: 0924 • ACR Convergence 2024
The Cytosolic DNA Sensor AIM2 Regulates Bone Homeostasis Through Bone Progenitor Cell Differentiation
Jia (Sijia) Chen¹, Yukiko Maeda², Catherine Manning³, Victor Le⁴, Jae-Hyuck Shim⁵, Katherine A. Fitzgerald⁶ and Ellen Gravallese⁷, ¹Brigham and Women's Hospital, Boston, MA, ²Sanofi, worcester, MA, ³Brigham and Women's Hospital, Dedham, MA, ⁴Digital Biology, Boston, MA, ⁵University of Massachusetts, Worcester, MA, ⁶UMass Chan Medical School, Worchester, MA, ⁷Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA
Background/Purpose: Innate sensing pathways and inflammasomes play an important role in autoimmunity and aging. AIM2 is a DNA sensor that triggers inflammasome assembly in myeloid…
Abstract Number: 2539 • ACR Convergence 2024
Telocytes Integrated into Mast Cells and Joint-Draining Lymphatic Vessels Potentially Regulate Lymphatic Clearance
Yue Peng¹, H. Mark Kenney², Karen Bentley¹, Lianping Xing³, Benjamin Korman⁴, Christopher Ritchlin⁵ and Edward Schwarz¹, ¹University of Rochester School of Medicine and Dentistry, Rochester, NY, ²University of Rochester School of Medicine and Dentistry, Henrietta, NY, ³University of Rochester School of Medicine and Dentistry, Webster, NY, ⁴University of Rochester, Rochester, NY, ⁵Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY
Background/Purpose: Rheumatoid arthritis (RA) patients and TNF-transgenic mice have lymphatic dysfunction (1). Recently, we showed mast cells involvement, as genetic ablation and drug inhibition decreased…
Abstract Number: 0068 • ACR Convergence 2024
Enhanced Expression of GPR65 in Inflammatory Sites and Bone Formation Regions in Ankylosing Spondylitis: Evidence from ScRNA-seq Analysis
Yong-Wook Park¹, Ki-Jeong Park², Sungsin Jo³, Tae-Hwan Kim⁴ and Tae-Jong Kim¹, ¹Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea, ²Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea, ³Hanyang University Institute for Rheumatology Research, Seoul, Republic of Korea, ⁴Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily affecting the axial skeleton. T helper 17 (Th17) cells play a pivotal role in the…
Abstract Number: 0925 • ACR Convergence 2024
Macrophages Produce Bone Anabolic Factors in Settings of Inflammation-Induced Bone Formation
Jia (Sijia) Chen¹, Megan Hanlon², Catherine Manning³, Susan MacLauchlan¹, Paul Hoover⁴, Christian Jacome-Galarza⁵ and Ellen Gravallese⁶, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women’s Hospital, Boston, MA, ³Brigham and Women's Hospital, Dedham, MA, ⁴Brigham and Women's Hospital, SWAMPSCOTT, MA, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA
Background/Purpose: Understanding the pathogenesis of inflammation-induced pathologic bone formation remains a significant challenge in spondyloarthritis patients. We thought to uncover the pivotal events driving the…
Abstract Number: 2542 • ACR Convergence 2024
Group 2 Innate Lymphoid Cells Aggravates Development of Inflammatory Arthritis
Anders Nguyen¹, Miriam Bollmann¹, Agnieszka Lastowska², Anna-Karin Hultgård Ekwall¹, Dietmar Zaiss³, Gary Firestein⁴ and Mattias Svensson⁵, ¹University of Gothenburg, Göteborg, Sweden, ²University of Gothenburg, Goteborg, Sweden, ³University Hospital Regensburg, Regensburg, Germany, ⁴University of California, San Diego, San Diego, CA, ⁵University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Activation of fibroblast-like synoviocytes (FLS) by immune cells drives inflammation and joint damage in rheumatoid arthritis (RA). Hence, understanding factors that induce destructive behaviors…
Abstract Number: 0073 • ACR Convergence 2024
Self or Bacteria-reactive Th17 Expand from Conventional and Regulatory T Cells in Parabacteroides Goldsteinii Gnotobiotic Arthritic SKG Mice, in Context of Interferon-driven Synovial Inflammatory Macrophages and Reduced Bacterial Immune Regulation
Benjamin Cai¹, Zewen Kelvin Tuong², Mark Morrison¹, Anne-Sophie Bergot¹ and Ranjeny Thomas³, ¹Frazer Institute, University of Queensland, Brisbane, Australia, ²Child Health Research Centre, University of Queensland, South Brisbane, Queensland, Australia, ³University of Queensland, Brisbane, Australia
Background/Purpose: In ankylosing spondylitis, spondyloarthritis (SpA) is often associated with gut inflammation. The strong genetic association with HLA-B27 and expanded CD8 TCR public clonotypes implicate…
Abstract Number: 0927 • ACR Convergence 2024
Synovial Macrophage Heterogeneity and Dynamics in Steady Stateand Rheumatoid Arthritis Mouse Model Time Course
Jessica Maciuch¹, Yidan Wang², Tyler Therron³, Harris Perlman¹ and Deborah Winter⁴, ¹Northwestern University, Chicago, IL, ²Northwestern University, Hanover Park, IL, ³Northwestern University, Chicago, ⁴Northwestern University, Skokie, IL
Background/Purpose: Macrophages are vital contributors to both pro-inflammatory signaling and tissue repair processes involved in the pathogenesis and remission of Rheumatoid Arthritis (RA). Recent research…
Abstract Number: 2543 • ACR Convergence 2024
Novel IgG Degrader BHV-1300 Demonstrates the Ability to Remove Anti-bDMARD ADA and Allows for Co-administration with Fc-containing Biologics
Elizabeth Dierks¹, Anna Bunin¹, Peter Ackerman¹, Dennis Heller², Frank Engler², Gene Dubowchik¹, David Spiegel³, Irfan Qureshi¹, David Pirman¹, Vlad Coric¹ and Bruce Car¹, ¹Biohaven Pharmaceuticals, New Haven, CT, ²Certara, Radnor, PA, ³Yale University School of Medicine, New Haven, CT
Background/Purpose: BHV-1300 is a molecular degrader of extracellular protein (MoDETM) in development for the treatment of IgG-driven autoimmune diseases, including rheumatoid arthritis. MoDEs are bifunctional…
Abstract Number: 0074 • ACR Convergence 2024
Tofacitinib Therapy Ameliorates Inflammation in a Mouse Model of Psoriasis and Arthritis by Inducing Type 2 Immunity
Maria de la Luz Garcia-Hernandez¹, Javier Rangel-Moreno¹, Ananta Paine², Angel Rangel-Garcia¹, Marissa Krantz³, Delaney Martino¹, Marc Nuzzo¹ and Christopher Ritchlin⁴, ¹University of Rochester, Rochester, NY, ²ORNA Tx, Southborough, MA, ³University of Rochester, Rochester, NY, ⁴Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY
Background/Purpose: Psoriatic arthritis (PsA), a chronic progressive inflammatory arthritis, affects peripheral joints and causes patient disability. PsA patients also have skin plaques initiated by activation…
Abstract Number: 0935 • ACR Convergence 2024
Molecular Degraders of Extracellular Protein (MoDEsTM) Rapidly and Effectively Remove Interstitial IgG and Disease-Relevant Immune Complexes Through Endo-lysosomal Degradation in the Liver
Charlotte Spliid¹, Seong Lee¹, Kathleen McGrath¹, Ana Estrella¹, Hanna Yousuf¹, Kathren Croce¹, Brett Rasile¹, Silvina Del Carmen¹, Ann Marie Rossi¹, Gene Dubowchik¹, David Spiegel², David Pirman¹, Anna Bunin¹, Vlad Coric¹ and Bruce Car¹, ¹Biohaven Pharmaceuticals, New Haven, CT, ²Yale University School of Medicine, New Haven, CT
Background/Purpose: Novel extracellular IgG degraders (BHV-1300/-1310) from the innovative molecular degraders of extracellular protein (MoDE) drug platform are being developed for the treatment of IgG-mediated…
Abstract Number: 2544 • ACR Convergence 2024
Spatial Transcriptomics Suggests Synovial Macrophage Niches Are Sexually Dimorphic in a Mouse Inflammatory Arthritis Model
Richard Bell¹, Ruoxi Yuan², Mary Huang², Ewurama Cann², Chao Yang², Franck Barrat¹ and Lionel Ivashkiv¹, ¹Hospital for Special Surgery, New York, NY, ²HSS, New York, NY
Background/Purpose: Monocytes and Macrophages (MФ) play a key pathogenic role in Rheumatoid Arthritis (RA), a disease that exhibits female sex bias. Recent work using scRNAseq…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.